MAPT and Alzheimer disease: Similarly, HRT use has been associated with greater brain volumes in key AD-relevant regions, such as the entorhinal cortex, the hippocampus and prefrontal cortex (Saleh et al., 2023; Coughlan et al., 2023) and lower levels of AD-relevant biomarkers, such as phosphorylated tau (p-tau) and total tau (t-tau) (Lee et al., 2024).